Message from the CEO
It is with great pride and enthusiasm that Green Cross Biotherapeutics Inc. is breaking new ground in Canada by building the country`s only intravenous immunoglobulin (IVIG) and albumin manufacturing facility. The Green Cross family has been providing patients with safe and effective healthcare solutions adapted to their evolving needs since its inception in 1967. The construction of this state-of-the-art bio-manufacturing centre and North American headquarters in Montreal is a cornerstone of our international growth strategy, and a historic milestone beneficial to the Canadian healthcare industry.
We are honoured that our extensive expertise will contribute to Canadians’ health. Moreover, we are excited to combine our imported knowledge and experience with the highly qualified people that we will be recruiting here. Quebec and Canada’s life science industries are well known worldwide for quality workers and their capacity to innovate. GCBT is thrilled to join a business community with such an outstanding reputation.
As an emerging global leader in the healthcare industry, our purpose is to provide our clients with the best and safest therapeutic products. GCBTs devotion to the healthy lives of people is our ultimate mission.
Even though we must still reach some important milestones before the commercial launch, GCBT is already fully active and planning for the years to come.
We thank you for your interest and will continue to dedicate our efforts to making this project a success for the life science industry and most of all, to move forward toward a healthier world.
CEO Young Ho Kim
Young Ho Kim, President and CEO of Green Cross Biotherapeutics